For patients with relapsed BRCA-mutated ovarian carcinoma, rucaparib produced a median OS of 19.4 months vs 25.4 months with chemotherapy in new findings.

The Prescription Drug User Fee Act (PDUFA) date refers to the deadline set by the US Food and Drug Administration (FDA) for reviewing a New Drug Application (NDA) or Biologics License Application (BLA ...

For both induction and maintenance therapy, subcutaneous guselkumab significantly improves clinical outcomes in patients with ...

Targeted molecular interventions in the replication cycle and the immune recognition of viruses are intended to prevent viral entry into cells and virus replication.

Guidance around complete revascularization and intracoronary imaging is strengthened, and Impella gets a recommendation.

USA News Group CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, Feb. 27, 2025 /PRNewswire/ -- USA News Group News Commentary - Now that World Cancer Day (Feb.

Teos' Belrestotug shows efficacy in trials, backed by a strong cash runway. Learn why ITOS stock might thrive with strategic ...

Childhood neuroblastoma is often a fatal disease. A new approach using a combination of two drugs shows promise in reducing ...

Metronomic capecitabine plus an aromatase inhibitor improved survival outcomes in hormone receptor-positive, HER2-negative ...

The study presents a useful computational analysis of how the ratio between excitatory and inhibitory neural numbers affects coding capacity. The authors show that increasing the proportion of ...

In a Chinese trial, trastuzumab rezetecan induced a 73% response rate in previously treated HER2-mutant non-small cell lung cancer (NSCLC). The safety profile of the novel antibody-drug conjugate was ...

Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing cancer therapies based on ...